Number of Intermediate- and High-Risk Factors Significantly Predicts Biochemical Survival and Prostate Cancer-Specific Survival After Low-Dose-Rate Brachytherapy

被引：0
|
作者：
Shasha, D. [1 ]
Salant, R. [1 ]
Sivathayalan, A. [2 ]
Farrell, P. J. [2 ]
Mourad, W. F. [1 ]
Harrison, L. B. [1 ]
机构：
[1] Mt Sinai Beth Israel Med Ctr, New York, NY USA
[2] Carleton Univ, Ottawa, ON K1S 5B6, Canada
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2015年 / 93卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2015.07.1172
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2617
引用
收藏
页码：E248 / E249
页数：2
相关论文
共 50 条
  • [41] Five-Year Treatment Outcome of High-Risk Prostate Cancer Following Radical Prostatectomy, Low-dose-rate, or High-dose-rate Brachytherapy
    Yoshiyama, Y.
    Kido, M.
    Yamamoto, T.
    Kimura, T.
    Miki, K.
    Aoki, M.
    Egawa, S.
    UROLOGY, 2012, 80 (03) : S346 - S346
  • [42] Biochemical Relapse-free Survival after External Beam Radiation and Brachytherapy for Prostate Cancer Patients Having Intermediate and High-risk Features
    Shasha, D.
    Nabhani, T.
    Nadelson, A.
    Patton, B.
    Salant, R.
    Harrison, L. B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S337 - S337
  • [43] Prostate-Specific Antigen at 4 to 5 Years After Low-Dose-Rate Prostate Brachytherapy Is a Strong Predictor of Disease-Free Survival
    Lo, Andrea C.
    Morris, W. James
    Lapointe, Vincent
    Hamm, Jeremy
    Keyes, Mira
    Pickles, Tom
    McKenzie, Michael
    Spadinger, Ingrid
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (01): : 87 - 93
  • [44] High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: Technical description and preliminary experience
    Prada Gómez P.J.
    De La Rua Calderón A.
    Fonseca I.R.
    Suárez M.E.
    García J.M.A.
    Rijo G.J.
    García J.F.
    Sancho J.M.G.
    García R.A.
    Rodríguez-Fernández R.
    Clinical and Translational Oncology, 2005, 7 (9) : 389 - 397
  • [45] Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options
    Skowronek, Janusz
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2013, 5 (01) : 33 - 41
  • [46] High-dose rate brachytherapy for high-risk prostate cancer
    Schenck, M.
    Krause, K.
    Schwandtner, R.
    Haase, I.
    Fluehs, D.
    Friedrich, J.
    Jaeger, T.
    Boergermann, C.
    Ruebben, H.
    Stuschke, M.
    UROLOGE, 2006, 45 (06): : 715 - +
  • [47] Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
    Morgan, Peter B.
    Hanlon, Alexandra L.
    Horwitz, Eric M.
    Buyyounouski, Mark K.
    Uzzo, Robert G.
    Pollack, Alan
    CANCER, 2007, 110 (01) : 68 - 80
  • [48] Prostate-specific antigen (PSA) nadir and experience of PSA bounce after low-dose-rate brachytherapy for prostate cancer predicts clinical failure
    Nakai, Yasushi
    Tanaka, Nobumichi
    Asakawa, Isao
    Onishi, Kenta
    Miyake, Makito
    Yamaki, Kaori
    Fujimoto, Kiyohide
    BRACHYTHERAPY, 2024, 23 (06) : 727 - 736
  • [49] Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer
    Barnes, Justin
    Kennedy, William R.
    Fischer-Valuck, Benjamin W.
    Baumann, Brian C.
    Michalski, Jeff M.
    Gay, Hiram A.
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2019, 11 (04) : 320 - 328
  • [50] Do androgen deprivation and the biologically equivalent dose matter in low-dose-rate brachytherapy for intermediate-risk prostate cancer?
    Tabata, Ryuji
    Kimura, Takahiro
    Kuruma, Hidetoshi
    Sasaki, Hiroshi
    Kido, Masahito
    Miki, Kenta
    Takahashi, Hiroyuki
    Aoki, Manabu
    Egawa, Shin
    CANCER MEDICINE, 2016, 5 (09): : 2314 - 2322
12345